Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celcuity Inc.CELC · Entity 3991 | Director | October 01, 2026 | October 05, 2026 |
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Director | June 11, 2026 | June 15, 2026 |
| INCYTE CORPINCY · Entity 3182 | Executive Vice President, CFO | July 16, 2018 | July 18, 2018 |
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | Director | December 30, 2020 | December 31, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celcuity Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 893 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 893 · Balance 893 F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.
Definium Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 19,900 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 4,666 · Balance 19,900 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10 | Direct | 19,188 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 19,188 · Balance 19,188 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
INCYTE CORP
Report date July 16, 2018 · Filed July 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,235 |
Reported balance
After 2018-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-07-16 · Tax withholding · Disposed 455 · Balance 10,235 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.
F2: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
PDL BIOPHARMA, INC.
Report date December 30, 2020 · Filed December 31, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 1,387 |
Reported balance
After 2020-12-30 transaction · row 1
1 source rowRow 1 · 2020-12-30 · Sale · Disposed 20,000 · Balance 1,387 |
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AERIE PHARMACEUTICALS INC
Report date November 21, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Disposition to issuer · Disposed 11,495 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy the Gryska Family Trust | 0 |
Reported balance
After 2022-11-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-11-21 · Disposition to issuer · Disposed 1,996 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-21 · Disposition to issuer · Disposed 16,854 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Forte Biosciences, Inc.
Report date August 27, 2026 · Filed August 27, 2026
Section 16 reporting ended · disclosed 2026-08-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Other · Disposed 5,940 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.50 · Expires 2033-01-10 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2033-09-19 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-27 · Disposition to issuer · Disposed 1,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2035-03-20 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-27 · Disposition to issuer · Disposed 31,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Stock Option (right to buy)]SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2034-08-20 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-27 · Disposition to issuer · Disposed 18,353 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 35,208 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F2: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F3: These stock options were granted with automatic vesting on exercisable date.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 49,003 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.25 · Expires 2024-05-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2025-05-15 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.82 · Expires 2026-05-20 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.60 · Expires 2027-05-19 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.77 · Expires 2028-05-18 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-14 · Disposition to issuer · Disposed 9,260 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.38 · Expires 2029-05-20 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-12-14 · Disposition to issuer · Disposed 7,038 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $160.33 · Expires 2030-05-15 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-12-14 · Disposition to issuer · Disposed 3,171 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $147.50 · Expires 2031-05-14 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-12-14 · Disposition to issuer · Disposed 3,462 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.63 · Expires 2032-05-13 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-12-14 · Disposition to issuer · Disposed 3,676 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2017 Filed Jul 5, 2017 20:12 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 599 | $129.74 | $77,714.26 |
DisclosureSEC source: 0001209191-17-043277 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,015 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 19,015 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:12 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 599 | $73.21 | $43,852.79 |
DisclosureSEC source: 0001209191-17-043277 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:50 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,756 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-17-039856 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,190 Underlying: Common Stock · 16,756 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:50 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 16,756 | $116.60 | $1,953,749.60 |
DisclosureSEC source: 0001209191-17-039856 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,015 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $115.35 - $120.00. F4 · balance_after: This includes an aggregate of 19,015 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:50 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 16,756 | $73.21 | $1,226,706.76 |
DisclosureSEC source: 0001209191-17-039856 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 00:19 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 60,729 | $2.47 | $150,000.63 |
DisclosureSEC source: 0000882104-17-000063 · wf-form4_149731312806511.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,163 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders. Read SEC document |
| May 19, 2017 Filed May 23, 2017 19:15 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,260 | $0.00 Strike: $66.60 | $0.00 |
DisclosureSEC source: 0001203311-17-000018 · edgardoc.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,260 Underlying: Common Stock · 9,260 shares Expires 2027-05-18 F3 · derivative.exercise_date: The option shall vest in full on May 18, 2018. Read SEC document |
| May 19, 2017 Filed May 23, 2017 19:15 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-17-000018 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,350 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Restricted stock units shall vest in full on May 18, 2018. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:39 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,389 | $0.00 Strike: $67.06 | $0.00 |
DisclosureSEC source: 0001209191-17-029297 · doc4.xml · derivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,725 Underlying: Common Stock · 1,389 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning October 31, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:39 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,389 | $124.26 | $172,597.14 |
DisclosureSEC source: 0001209191-17-029297 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,015 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 11,187 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:39 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,389 | $67.06 | $93,146.34 |
DisclosureSEC source: 0001209191-17-029297 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 39,789 | $0.00 Strike: $67.06 | $0.00 |
DisclosureSEC source: 0001209191-17-026564 · doc4.xml · derivative · entry 6 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,114 Underlying: Common Stock · 39,789 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning October 31, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,739 | $0.00 Strike: $67.06 | $0.00 |
DisclosureSEC source: 0001209191-17-026564 · doc4.xml · derivative · entry 5 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,734 Underlying: Common Stock · 1,739 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning October 31, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:14 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 39,789 | $138.00 | $5,490,882.00 |
DisclosureSEC source: 0001209191-17-026564 · doc4.xml · nonDerivative · entry 4 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,015 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $136.10 - $140.71. F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:14 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,739 | $138.00 | $239,982.00 |
DisclosureSEC source: 0001209191-17-026564 · doc4.xml · nonDerivative · entry 3 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,804 F1 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $136.10 - $140.71. F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 39,789 | $67.06 | $2,668,250.34 |
DisclosureSEC source: 0001209191-17-026564 · doc4.xml · nonDerivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,739 | $67.06 | $116,617.34 |
DisclosureSEC source: 0001209191-17-026564 · doc4.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:48 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,091 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004542 · doc4.xml · derivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,091 Underlying: Common Stock · 19,091 shares Expires 2027-01-16 F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 19:21 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001203311-16-000153 · edgardoc.xml · derivative · entry 2 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in full on May 24, 2008. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 19:21 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 10,000 | $10.20 | $102,000.00 |
DisclosureSEC source: 0001203311-16-000153 · edgardoc.xml · nonDerivative · entry 1 GRYSKA DAVID W · CIK 0001202335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.